TissueTech Completes $15M Series B Financing

TT-trio-logosTissueTech, Inc., a Miami, FL-based regenerative tissue engineering company, completed a $15m Series B financing.

Backers included River Cities Capital Funds and Ballast Point Ventures.

Led by Amy Tseng, CEO., and Dr. Scheffer Tseng, MD, PhD, Chairman and Chief Scientific Officer, TissueTech offers its portfolio of amniotic membrane and umbilical cord-based tissue and device products through its commercial subsidiaries Bio-Tissue Inc., a provider of regenerative biologic therapies and ocular hygiene solutions for the treatment of ocular surface diseases and disorders, and Amniox Medical Inc., a provider of regenerative tissue therapies to the musculoskeletal and wound care markets.

The funding will accelerate sales, marketing, and further research and development in both divisions.



Join the discussion